The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ADIL | -83.26% | -99.8% | -71.25% | -100% |
| S&P | +12.16% | +74.91% | +11.82% | +141% |
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson & William B. Stilley in November 2010 and is headquartered in Charlottesville, VA.
No news articles found for Adial Pharmaceuticals.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$0.14K | 0.7% |
| Market Cap | $192.91M | 20.6% |
| Market Cap / Employee | $27.56M | 0.0% |
| Employees | 7 | 0.0% |
| Net Income | -$1,793.65K | 18.2% |
| EBITDA | -$1,763.94K | 20.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.61M | -11.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -130.16% | 141.9% |
| Return On Invested Capital | -324.29% | -40.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,833.37K | -8.2% |
| Operating Free Cash Flow | -$1,833.37K | -8.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 27.49 | 25.23 | 23.62 | 34.04 | 35.77% |
| Price to Tangible Book Value | 27.51 | 25.25 | 23.66 | 34.06 | 35.72% |
| Enterprise Value to EBITDA | -1.44 | -0.79 | 1.44 | -1.83 | 547.62% |
| Return on Equity | -323.8% | -217.0% | -171.3% | -155.0% | -51.09% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
